President of investment company A1, the control means shareholders "Alfa Group", Alexander Vinokurov became the controlling shareholder of the pharmaceutical distributor "SIA International", said RBC senior manager of one of the pharmaceutical companies. According to him, the deal was closed in December 2015. What Vinokurov became co-owner of the company, RBC earlier confirmed his representative, without specifying the size of the purchased package and its cost. "Pharmaceutical Bulletin" earlier, citing a source close to the negotiations, noted that the heirs of the founder of "SIA International" Igor Rudinsky retain the part of the business. The "SIA International" could not provide comment on Monday, RBC. The press service of the A1 to the inquiry said they did not comment on personal projects managers.
Deputy Director General of Stada CIS Ivan Glushkov evaluates the maximum value of "SIA International" without taking into account the debt of 7-8 billion rubles. Development Director Nikolai Bespalov RNC Pharma SIA estimates more expensive - at 8-10 billion rubles.
AdvertisingClick on the video to go to the advertiser's siteRepresentative Alexander Vinokurov said that the businessman came to the capital of SIA for several reasons: Vinokourov knew the founder of "SIA International" Igor Rudinsky "many years" after the death of Rudinsky his family appealed to Vinokurov to help restructure the company's business, Vinokourov and the new team "SIA International "see the prospects of development of the Russian pharmaceutical industry and companies in this market. In early February, according to the register, the company replaced CEO of SIA. They became the new manager for the pharmaceutical market Alexander Dyomkin. According to SPARC, Dyomkin also the CEO of LLC "Everest Group" and LLC "Tuvaasbest", are engaged in the extraction of asbestos.
The main priority is the return of Vinokourov in the pharmaceutical distribution market leading position, said his spokesman. One of the largest pharmaceutical distributors Russia "Protek" did not comment on RBC issues related to the SIA. However, the main owner of "R-Pharm" Alexey Repik believes that the SIA has every chance to regain the lead.
Who is Alexandre Vinokourov
Forbes magazine has included a 33-year-old Alexander Vinokourov in the list of highest-paid young top managers. He began his career in 2003 as an intern in the investment bank Morgan Stanley, and three years later became a co-director of the Russian office of TPG Capital Fund.
In 2008, Alexandre Vinokourov married the daughter of the Minister of Foreign Affairs Sergey Lavrov.
In the summer of 2011, Vinokourov became the first vice-president of the "Amount" Ziyavudin Magomedov, then, in 2012 - the president of the company. At the end of 2014 he led the investment company A1.
As SIA ceased to be the first
Igor Rudinskiy founded "SIA International" in 1993. According to DSM Group rating, the company became the first in terms of turnover among Russian pharmaceutical distributors in 2007. Now in this ranking it ranked fifth. In the ranking of the largest pharmaceutical distributors in Russia, compiled by RNC Pharma for the first nine months of 2015, "SIA International" took seventh place with a market share of 7.6% (in the same period of the previous year the company's share was 8.1%, see table.).
Igor Rudinskiy died in October 2014 after a long illness. "R-Pharm" Even during his lifetime, he has agreed to sell a controlling stake of the company group. In March 2015 the transaction was approved by the Federal Antimonopoly Service. However, in the summer of 2015, the company decided to withdraw from the transaction, RBC said the owner of the "R-Pharm" Alexey Repik. "We decided to concentrate on the production of drugs and leaving them on the international markets", - he explained.
According to SPARC, revenue of JSC "SIA International Ltd" in 2014 amounted to 98.5 billion rubles. - 31% more than in 2013. Net income in 2014 - almost 144 million rubles. In 2015, "SIA International" was an active participant in the courts, both as plaintiff and as a defendant. According to the SPARK database, the company has filed about 150 claims totaling almost 3.5 billion rubles. The very same SIA acted defendant in 67 lawsuits in the amount of 5.3 billion rubles. The claim for 305 million rubles. applied to the BIA, in particular pharmaceutical producer Gedeon Richter. In Gedeon Richter declined to comment.
In the last three or four years, "SIA International" significantly worsened their financial performance, said Bespalov from RNC Pharma. "Among all rested on Igor Rudinskiy, - he explains. - In the last years before his death, he was seriously ill, and it was difficult to manage the company. He tried to retire, chose the people who passed the management of the company, but they do not live up to his expectations. "
At Alexander Vinokourov and his father, Semyon Vinokourov already have assets in the pharmaceutical business. Together with a partner, Sergei Zhukovsky Alexandre Vinokourov and his father Semen Vinokurov own company "Genfa" engaged in distribution and localization of drugs, confirmed RBC representative Vinokourov Bush. This company was founded in 2006, according to SPARK data base, its revenue in 2014 amounted to 47.8 million rubles, net loss of -. 208 700 000 rubles. Now the key product for "Genfy" is an anticancer drug "Genfatinib", which commissioned by the company is produced abroad, says development director of RNC Pharma Nikolai Bespalov. According to him, in 2015 "Genfa" was to make money by selling "Genfatiniba" 50-60 million rubles. Also, "Genfa" is engaged in the packaging of medicines under a contract for the Kurgan plant "Synthesis", which is co-owned "SIA International" and "Rostec".

"Rostec» Partner
In September 2014 the State Corporation "Rostec" and pharmaceutical company "Genfa" signed a memorandum on establishing a joint venture, investment in which amounted to $ 100 million, according to the official website of "Genfy". The purpose of the joint venture - localization of production of drugs with access to the complete cycle of development, clinical trials, production and distribution of drugs, the company said. "The company will combine three parts: biotechnology, oncology drugs, as well as antibiotics and hormonal agents. It is planned to develop its own line of import substitution drugs (30 products) and production of generic drugs already existing in the most difficult and the key segments of the market (oncology, neurology, nephrology, hematology, etc.). Total production is expected around 60 foreign drugs ", - stated in a press release" Genfy ". The pad to accommodate the company planned to pick up the end of 2015, the plant itself going to be built within 2015-2016. However, until the project is only at the stage of developing a business plan, he clarified RBC representative "Natsimbio" ( "daughter" of "Rostec").
Vinokourov representative, replying to the questions of RBC, said that the new co-owner of SIA SIA is not the intention to unite and "Genfu" as is "different businesses."
Now before Vinokourov task is to build on the basis of SIA and "Genfy" profitable pharmaceutical business, which would include logistics and production, says Ivan Glushkov. "Vinokourov will try to repeat the company's business model" R-Pharm ", - he believes. - That is, "Genfy" together with "Natsimbio" will have its own production in Russia will be a major plus distributor. As part of the import substitution policies is a good model. "
"Perhaps the SIA will be the supplier for the market in the state, - said Bespalov from RNC Pharma. - Probably, the company does not unite with "Natsimbio" or "Rostec" but will carry out delivery of the drugs to be produced in conjunction with the State Corporation ". The RBC "Natsimbio" clarified that currently the company has no plans to acquire a stake in "SIA International".
More details on the RBC: